Nutex Health Inc

Nutex Health Inc(NUTX)の株式分析

$189.250

-4.542 (-2.40%)終値時点

Loading chart…
High
196.439
Open
190.990
VWAP
191.55
Vol
130.32K
Mkt Cap
29.33M
Low
188.950
Amount
24.96M
EV/EBITDA, TTM
2.54

Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates over 27 facilities in 12 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization, it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.

AI analysis of Nutex Health Inc (NUTX)

buy

Nutex Health Inc is a good buy right now due to its recent strong earnings performance, reporting a net income of $65.8 million and an EPS of $9.38, which significantly exceeded expectations. Additionally, the stock is currently priced at $189.25, with a low forward P/E ratio of 0, indicating potential for growth. The main risk is the recent revenue decline to $210.8 million, down from $244 million a year ago, which could impact future performance.

バリュエーション指標

The current forward P/E ratio for Nutex Health Inc (NUTX) is 0.00, compared to its 5-year average forward P/E of -23.41.

Forward P/E

Fair
5Y Average P/E
-23.41
Current P/E
0.00
割高
72.87
割安
-119.68

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
51.63
Current EV/EBITDA
2.54
割高
154.01
割安
-50.74

Forward P/S

Fair
5Y Average P/S
2.75
Current P/S
1.38
割高
9.43
割安
-3.92

Alphio AI Price Scenarios for NUTX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NUTX

$429.67

シナリオ価格

B

Base

Base · 50%NUTX

$391.67

シナリオ価格

B

Bear

Bear · 25%NUTX

$341.69

シナリオ価格

Whales holding NUTX

D

Divisadero Street Capital Management, LP

+ HoldingNUTX

+7.83%

3M Return

イベントタイムライン

2026-04-30 (ET)

17:20:00

Nutex Health Reports Q1 Revenue of $216.49M

2026-03-06 (ET)

09:00:00

Oil Prices Surge as Markets Decline Due to Geopolitical Risks

08:10:00

Nutex Health Reports $11.8M Net Income for Q4 2025

2026-03-05 (ET)

19:30:00

Marvell Technology Shares Rise 15% After Earnings

18:50:00

Nutex Health Reports 2025 EPS of $10.48 vs. $9.69 in 2024

ニュース

NUTX FAQ — answered by Alphio AI

Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates over 27 facilities in 12 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization, it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities. It operates in the Healthcare sector (SERVICES-BUSINESS SERVICES, NEC industry).

Nutex Health Inc is a good buy right now due to its recent strong earnings performance, reporting a net income of $65.8 million and an EPS of $9.38, which significantly exceeded expectations. Additionally, the stock is currently priced at $189.25, with a low forward P/E ratio of 0, indicating potential for growth. The main risk is the recent revenue decline to $210.8 million, down from $244 million a year ago, which could impact future performance.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める